Michael J. Fox has spent decades navigating Parkinson’s disease while continuing to shape the conversations about the ...
This post is the first in a five-part series summarizing APDA’s recent “Ask the Expert” event on Smart Patients. During the ...
North Carolina author, artist, and craftsperson draws inspiration from family, heritage, creativity, and personal experiences to create books for children and adults. New York City, NY, September 29, ...
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first ...
Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...
People living with Parkinson’s disease are hospitalized more often than other older adults, most often because of infections, falls, fractures, or other medical problems rather than Parkinson’s itself ...
Daily Mail on MSN
Mike Tindall opens up about harrowing final weeks of his father's life after his death aged 80
The former England rugby star, 47, said it was 'a relief' that his father was now 'free of his body', and said the experience ...
Since its inception in 2000, The Michael J. Fox Foundation has become the world’s largest nonprofit funder of Parkinson’s ...
The FDA has approved AbbVie's JUVMO (tavapadon), as the first and only selective D1/D5 receptor agonist for adults with ...
People connected to the Northstars' girls volleyball program have had family members with Parkinson's disease.
The FDA approved a new once-daily Parkinson’s pill in the dopamine agonist class, designed to selectively target receptors ...
The FDA has approved Juvmo, an oral tavapadon treatment for adults with Parkinson’s disease, following three pivotal phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results